In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates

被引：8
|
作者：
Zaoutis, T
Moore, LS
Furness, K
Klein, JD
机构：
[1] Alfred I duPont Hosp Children, Div Pediat Infect Dis, Wilmington, DE 19899 USA
[2] Christiana Hosp, Christiana Care Hlth Syst, Infect Dis Lab, Newark, DE USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 07期
关键词：
D O I：
10.1128/AAC.45.7.1952-1954.2001
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activities of meropenem, linezolid, quinupristin dalfopristin, vancomycin, and penicillin against 130 clinical isolates of group C and G streptococci, including vancomycin-tolerant isolates, were evaluated. Meropenem, linezolid, quinupristin-dalfopristin, vancomycin, and penicillin MICs at which 90% of the isolates were inhibited were 0.06, 2.0, 0.25, 0.5, and less than or equal to0.016 mug/ml, respectively. Meropenem, linezolid, quinupristin-dalfopristin, and penicillin were active against group C and G streptococci, including vancomycin-resistant strains.
引用
收藏
页码：1952 / 1954
页数：3
相关论文
共 44 条
  • [21] Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model
    Cha, R
    Akins, RL
    Rybak, MJ
    PHARMACOTHERAPY, 2003, 23 (12): : 1531 - 1537
  • [22] In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against staphylococcus aureus clinical isolates
    Millán, L
    Cerdá, P
    Rubio, MC
    Goñi, P
    Canales, M
    Capilla, S
    Oca, M
    Gómez-Lus, R
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (03) : 230 - 237
  • [23] Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae
    Frédénucci, I
    Chomarat, M
    Bercion, R
    Carricajo, A
    Celard, M
    Croizé, J
    Delubac, F
    Fèvre, D
    Fuhrmann, C
    Helfre, M
    Letouzey, MN
    Lelièvre, H
    Mandjee, A
    Marthelet, P
    Meley, R
    Perrier-Gros-Claude, JD
    Ros, A
    Roure, C
    Smati, S
    Thierry, J
    Tous, J
    CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (10) : 680 - 683
  • [24] A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago, L.
    Nicola, L.
    De Vecchi, E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (06) : 608 - 611
  • [25] Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin
    von Eiff, C
    Reinert, RR
    Kresken, M
    Brauers, J
    Hafner, D
    Peters, G
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (08) : 2819 - 2823
  • [26] In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method
    Abb, J
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (04) : 319 - 321
  • [27] Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group:: Comparison with the activities of 14 other agents
    Betriu, C
    Gómez, M
    Palau, ML
    Sánchez, A
    Picazo, JJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) : 2320 - 2322
  • [28] In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model
    Allen, GP
    Cha, R
    Rybak, MJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2606 - 2612
  • [29] In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea
    Hwang, SH
    Kim, MN
    Pai, CH
    Huh, DH
    Shin, WS
    YONSEI MEDICAL JOURNAL, 2000, 41 (05) : 563 - 569
  • [30] Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model
    Cha, R
    Rybak, MJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) : 1984 - 1987
12345